Gibson, Dunn & Crutcher advised Jade Biosciences on the transaction, and Cooley advised the placement agents; while Goodwin Procter advised Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Goodwin advised Isomorphic Labs on its strategic research collaboration with Novartis. Isomorphic Labs has signed a strategic research collaboration with Novartis to discover small molecule therapeutics against...
You must be a Standard 1 Year member to access this content.
Goodwin advised Flagship Pioneering on the matter. Hogan Lovells acted for Omega Therapeutics, Inc. Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) and Cellarity Inc. announced that Novo Nordisk...
You must be a Standard 1 Year member to access this content.
Goodwin advised Rapport Therapeutics on the fundraising. Rapport Therapeutics announced the completion of its $150 million in Series B funding. Led by Cormorant Asset Management, the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Rapport Therapeutics, Inc. on the deal. Rapport Therapeutics, Inc. announced its launch with a $100 million Series A financing from Third Rock Ventures, ARCH...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Alnylam Pharmaceuticals, Inc. on the deal, while Davis Polk advised the representative of the initial purchasers. Alnylam Pharmaceuticals, Inc. announced its inaugural offering...
You must be a Standard 1 Year member to access this content.
